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Background: Oesophageal carcinoma is a rare disease with often dismal prognosis. Despite multiple trials addressing
specific issues, currently, many questions in management remain unanswered. This work aimed to specifically address
areas in the management of oesophageal cancer where high level evidence is not available, performing trials is very
demanding and for many questions high-level evidence will not be available in the forseeable future.
Methods: Two experts of each national, oesophageal cancer research group from Austria, France, Germany, the
Netherlands and Switzerland were asked to provide statements to controversial issues. After an initial survey, further
questions were formulated and answered by all experts. The answers were then discussed and qualitatively analysed
for consensus and controversy.
Results: Topics such as indications for PET-CT, reasons for induction chemotherapy, radiotherapy dose, the choice of
definitive chemo-radiotherapy versus surgery in squamous cell cancer, the role of radiotherapy in adenocarcinoma and
selected surgical issues were identified as topics of interest and discussed.
Conclusion: Areas of significant controversy exist in the management of oesophageal cancer, mostly due to high-level
evidence. This is not expected to change in the upcoming years.
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ChemotherapyIntroduction
Oesophageal carcinoma is a relatively rare disease with
a still dismal prognosis despite having seen some im-
provement in management over the last decade mainly
reflecting better patient selection, more effective neo-
adjuvant therapy and improved perioperative manage-
ment. There remain many unresolved issues and existing
controversies. Published clinical trials often provide in-
sufficient answers for individual patients; too many vari-
ables influence the treatment decision such as different
histologies implying different clinical biology, the loca-
tion of the tumour influencing the preferred technique
of surgery and radiotherapy or significant co-morbidities* Correspondence: thomas.ruhstaller@kssg.ch
11Department of Haematology and Oncology, Swiss Group for Clinical
Cancer Research (SAKK), Kantonsspital St. Gallen, St. Gallen, Switzerland
Full list of author information is available at the end of the article
© 2015 Putora et al. This is an Open Access ar
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/of the patient. With the relative rarity of this disease and
the requirement for intensive teamwork in diagnostics
and therapeutics, large multi-centre studies are difficult
to perform and are often underpowered and their results
may be challenging to translate into clinical practice.
Clinicians must make decisions despite gaps in evidence
and many issues will not be solved within clinical trials
over the next decade. In an attempt to provide guidance
in these situations [1], various consensus methodologies
have been established [2, 3]. Consensus meetings typically
gather specialists in a field, facilitate exchange of opinions,
and usually result in a minimal consensus statement. In
2012, under the auspices of the EORTC, a consensus
meeting was held in St. Gallen, Switzerland with the aim
to produce a consensus statement on “the primary therapy
of gastric, gastro-oesophageal and oesophageal cancer-
differential treatment strategies for subtypes of earlyticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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did provide minimal consensus on various issues, many
questions remained unanswered.
The aim of this work is focussing particularly on contro-
versial issues in the therapy of locally advanced oesophageal
cancer in contrast to the published minimal consensus
statement. Prominent representatives of the national can-
cer research groups (NCRG) dealing with oesophageal
cancer from Austria, France, Germany, the Netherlands
and Switzerland discussed these issues and explained their
views and opinions and provided practical advice. The aim
of this work is to demonstrate the spectrum of opinions
on various critical issues and provide practical approaches
where evidence is not available.
We hope our work will support clinicians in their daily
practice and research groups in determining areas for fu-
ture studies.
Methods
After the first EORTC consensus meeting on treatment
standards in St. Gallen 2012 the idea of a more de-
tailed discussion of the unresolved controversies came
up. Leaders of several European cancer research groups
were asked to support this initiative. Representatives of
the French Group FFCD (“Federation Francophone de
Cancérologie Digestive”), the Swiss Group for Clinical
Cancer Research (SAKK), the German Oesophageal Study
Group, the Austrian Group (West-Austrian Study group)
and the Dutch Group (CROSS study group) agreed to par-
ticipate; whereas the Upper GI Clinical Studies Group of
the National Cancer Research Institute UK was invited
but decided not to participate. From each participating
group two representatives of different therapeutic disci-
plines were determined, in summary: 3 surgeons, 5 med-
ical oncologists and 2 radiation oncologists, additionally
one Swiss radiation oncologist (PMP), the co-initiator, was
part of the study team.
Based on the consensus statement on oesophageal cancer
published in 2012 a catalogue of controversial issues and
questions was generated. An initial draft was then sent to
the representatives of each group with the request to answer
the proposed questions of controversy based on the opin-
ions and standards within their national research group.
After receiving the first answers to the survey, several
questions were further specified based on obtained input.
Participants were once again invited to add further ques-
tions they considered of interest. After including the new
questions, every participant received the survey (Additional
file 1) again, this time including the responses from all par-
ticipants. Following this, a third round was initiated to pro-
vide room for clarifications, questions and answers and
also discussions between the different groups.
After the final list of answers was collected, questions
considered of little relevance or those without generalinterest were discarded. The remaining statements were
summarised by topics. Based on these and a further dis-
cussion among all, the representatives were asked to pro-
vide a statement of support or comment on all issues.
This manuscript intentionally also addresses topics where
no consensus was reached in order to highlight the contro-
versies; explanations of different opinions were included.
The expressed opinions from the prominent represen-
tatives of the research groups were not distributed and
compared in their national groups; However, the leaders
have been involved in the design and execution of several
study protocols in this field and also have insight into on-
going trials within their research groups.Results
PET-CT-SCAN
Should PET-CTs be used for staging?
All NCRGs consider 18-FDG-PET-CT scans a useful
tool for the detection of additional metastases, particu-
larly for locally advanced tumours. Experts from France
did not recommend routine use of PET-CTs, especially
when EUS and CT scans are performed in expert
centres. Although a relatively high proportion of ACs
might not show FDG avidity, the recommendations were
independent of histology. The diagnosis “oesophageal
cancer” is sufficient for reimbursement in Switzerland
and France and soon in the Netherlands. Though not
systematically re-imbursed, most centres in Austria and
Germany make use of PET-CTs for patients with
oesophageal carcinomas. However, in Germany and the
Netherlands the missing reimbursement is a limiting
factor. The new guidelines in the Netherlands will
recommend PET-CTs for pre-treatment staging as well
as for re-staging after neoadjuvant radiochemotherapy.PET-CTs for radiation therapy treatment planning?
In addition to staging, PET-CT is being incorporated in
radiotherapy planning in all NCRGs, it appears to be es-
pecially relevant for lymph nodes marginally outside the
standard radiotherapy treatment volumes. In Austria the
PET-CT is also used to plan a radiotherapy boost. In the
Netherlands, radiotherapy volumes are only adapted based
on lymph nodes outside the planned field after invasive
verification (EUS-FNA/FNB).How do you deal with PET-positive hilar lymph nodes?
Major variations were observed for the management of
PET-positive hilar lymph nodes. The different opinions
reached from considering FDG-positive hilar lymph nodes
of normal size not pathologic to considering them meta-
static disease. The patterns of practice are depicted in
Table 1.
Table 1 Management of PET-positive hilar lymph nodes
France Positive hilar lymph nodes of normal size are not considered pathologic. Since they are generally associated with other lymph node
sites, a neoadjuvant chemotherapy is provided. if right-sided location: removed at time of EC surgery; if left-sided location: cytological
verification required and if positive: included in the radiation field
Netherlands FNA/Biopsy: if malignant, usually considered to be distant metastases
Germany The radiation portals are modified to include the PET-positive nodes
Austria Treated if tumour location is in the middle third of the oesophagus and nodes are enlarged on CT
Switzerland If positive lymph nodes are small (<1.5 cm) and patient is a smoker, no further investigations recommended. If the lymph nodes are
larger and without other plausible cause, FNA is performed. If positive, included in radiotherapy field.
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Although level 1 evidence for induction chemotherapy
before CRT is missing, most NCRGs are using induction
chemotherapy in their study protocols. Several reasons
may justify induction chemotherapy (see Table 2). Hist-
ology plays no role in this decision, it is also independent
of further therapy, CRT followed by surgery or definitive
CRT, respectively. In the Netherlands and in France rou-
tine use of induction chemotherapy is not considered.
Most centres consider two – three cycles adequate, not
delaying surgery excessively. The reasons to consider in-
duction chemotherapy are listed in the Table 2, however
this approach remains highly controversial.
SCC of esophagus
When should definitive chemo-radiation be preferred over a
surgical approach?
According to the consensus conference all countries ex-
cept the Netherlands and France prefer definitive CRT
for tumours located in the upper thoracic oesophagus.
They do not start to evaluate surgery unless the prox-
imal edge of the tumour has clearly 4–5 cm distance
from the entrance of the oesophagus (thoracic inlet). In
the Netherlands and in France only cervical oesophageal
cancer is treated with CRT only, surgery is evaluated for
all intra-thoracic tumours.
The following reasons were named by all parties as lead-
ing to a preference for definitive CRT over surgery inde-
pendent of the location: patient preference, co-morbidities,
high biological age and high perioperative risk. Add-
itionally tumours infiltrating the laryngeal nerve, the upper
oesophageal sphincter, thoracic aorta or the tracheo-
bronchial tree are also unsuitable for operation. ForTable 2 Reasons to consider induction chemotherapy
• rapid start of treatment • fast improvement of dysphagia,
feeding tubes can nearly always be
avoided
• test of patient compliance
also to consider further
therapy decisions
• increase of compliance of the
following CRT because of better
nutritional status and less dysphagia
• in vivo testing of chemotherapy
before the start of radiotherapy
• more and early systemic treatment
for possible metastatic disease (most
patients still die of systemic disease)tumours invading the tracheo-bronchial tree, starting
treatment with neoadjuvant chemotherapy alone to pre-
vent fistula was recommended. A large tumour mass and
a tumour extending >10 cm could also be reason to prefer
definitive CRT.
How to proceed after cCR after neodjuvant
radiochemotherapy?
In Germany and in France omitting the operation would
be considered a reasonable alternative outside of clinical
trials and an option after discussion with the patient.
In all other countries this approach would explicitly not
be considered a standard and the operation would be rec-
ommended in spite of cCR after neoadjuvant therapy.
Which dose of radiotherapy is justified for neoadjuvant or
definitive CRT?
There was controversy about the correct dose of radio-
therapy, however all NCRGs agreed that when individual
patient characteristics were considered (poor performance
status, comorbidities, age..) any dose in the mentioned
range would be considered acceptable. There was no clear
recommendation on the use of a radiotherapy boost apart
from Austria. A dose that is considered feasible by all
was 45 Gy in the neoadjuvant setting and ranging
from 50. 4 Gy to 60 Gy for definitive radio-chemotherapy
with 1.8 Gy to 2.0 Gy per fraction 5x per week (Table 3).
Radiotherapy dose escalation (64.8 Gy vs. 50.4 Gy) within
definitive radio-chemotherapy was investigated in a phase
III RTOG 9405/INT 0123 trial [5], however due to a high
number of early deaths in the high dose arm, the results
are perceived as controversial. It has to be realised that
the more often performed rescue surgery after definitive
CRT and local relapse is associated with a higher risk of
postoperative morbidity if a radiotherapy dose of more
than 50 Gy was applied.
How should patients be restaged after neoadjuvant CRT?
EUS after neoadjuvant CRT was not considered relevant.
When patients are restaged to prepare for surgery, a CT
scan is performed by all NCRGs. In France, Germany and
Austria endoscopy is repeated, while PET-CT for re-staging
is not performed routinely outside of studies after
Table 3 Radiation doses used for neoadjuvant as well as
definitive radiochemotherapy
Neoadjuvant: Definitive:
45 Gy (France, Austria,
Switzerland)
50.4 Gy, without boost (France, Netherlands)
At least 60 Gy (Germany)
41.4 Gy (Netherlands) 50.4 Gy to 59.4 Gy +/− brachytherapy
boost (Austria)
40–50 Gy (Germany) In Switzerland very heterogenous opinions
from 50.4 Gy to 59.4 Gy (without boost
or brachytherapy)
Table 4 Implementation of minimally invasive oesophagectomy
Austria No general consensus about technique, but in some
specialised centres either laparoscopy or thoracoscopy is
performed in the surgical treatment of oesophageal
cancer. Most of these use hybrid techniques, i.e. one part
minimal invasive, the other part open.
France Hybrid minimally invasive is routine in experienced centres
with laparoscopic gastric mobilisation and open thoracotomy.
The aim is to decrease the rate of major postoperative
pulmonary complications. Thoracoscopic oesophagectomy
is reserved for high-grade dysplasia or early tumour, because
it is considered that large en bloc resection for locally
advanced cannot be safely done in routine
Germany Minimal invasive surgery for the thoracic part is meanwhile
the preferred in the participant’s centre (Essen), but there is
no consensus in the group.
Netherlands MIO is mainly applied for early cases. Main advantage: less
pulmonary complications. After the Dutch RCT MIO is
gradually also accepted for more advanced cases
Switzerland Minimally invasive surgery is a good option for the
thoracic part, especially when a cervical anastomosis is
done. Others prefer a laparascopic gastric mobilisation
followed by open thoracotomy and a thoracic
anastomosis. There is no consensus in the group.
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for restaging after CRT are recommended.
When omitting surgery is considered in case of cCR
several biopsies in the tumour area were considered
mandatory and non-invasive imaging alone insufficient.
Esophago-gastric junction adenocarcinoma (Siewert I
and II)
The treatment of choice is generally neoadjuvant CRT.
In France, as well as in Germany, neoadjuvant / perioperative
chemotherapy is standard for adenocarcinoma Siewert
type II, except R0 resection is not deemed achievable. It is
worth mentioning that the differentiation between Siewert
types may be difficult in some cases despite radiographic
or even endoscopic data. All agreed that the preference to
include radiotherapy increased with extension into the
oesophagus. Neoadjuvant chemotherapy alone was the
second best option, but should trimodality therapy be
considered too risky (e.g. comorbidities, risk of surgery)
then omitting radiotherapy instead of surgery would be
preferred. This is obviously in contrast to SCC of the
oesophagus. Definitive chemoradiotherapy was considered
an option only if the other two previously mentioned
treatments were not possible (“third best option”). Most
agreed that coeliac lymph-nodes would be included in the
radiation fields, in the Netherlands these would be omit-
ted if clinically bland.
Surgical issues
Preferred oesophagectomy technique?
Transthoracic en-bloc esophagectomy with two-field
lymphadenectomy in a one-stage procedure was pre-
ferred by all. The anastomosis would be preferred to be
intra-thoracic at the upper part of the thorax (France,
Austria) or cervical (Netherlands), with no consensus
among the surgeons in Germany and Switzerland. Cer-
vical anastomosis was preferred for those with upper-third
cancers (in order to reach microscopically negative prox-
imal margins; or because of better prognosis in case of
leakage). Upper intrathoracic anastomosis was preferred
over cervical due to lower percentage of leakages and
lower stricture rates.The use of minimally invasive oesophagectomy (MIO)
Despite limited follow-up and high requirements in ex-
pertise, in most centres MIO was considered an option,
however the implementation was highly variable among
the centres responding (see Table 4).
What are the indications for a transhiatal resection in
oesophago-gastric junction carcinoma (Siewert type I
or II)?
Most agreed on transhiatal resection for Siewert II Tumour
(Austria, Netherlands, Switzerland, Germany) and transthor-
acal approach for Siewert I tumours. Thoracotomy would be
preferred for both. In France, the transhiatal approach would
be reserved for patients not tolerating thoracotomy.
Which surgical technique is preferred for the special case of
a SCC at the oesophago-gastric junction?
Transthoracic resection in all squamous cancers was pre-
ferred in France, the Netherlands and Austria independent
of the location. Transmediastinal esophagectomy would
be an alternative in combination with bilateral medias-
tinal “en bloc” lymphadenectomy (para-aortic nodes, para-
oesophageal nodes, pulmonary left and right hilar nodes
including those of the tracheal bifurcation) as a two field
lymphadenodectomy in Switzerland. This would also be
considered in Germany after CRT.
Discussion
Our analysis identified consensus as well as controver-
sies in the management of oesophageal cancer, particularly
where evidence is missing. These results were influenced
by the selection of groups and their representatives.
Table 5 A selection of prospective trials in localised oesophageal cancer in the participating countries
Group/Name of the trial Background Objectives Endpoints Design Sample size (planned) date of
trial initiation
SAKK 75/08 (Swiss, German, Austrian
and French centers) NCT01107639
Multimodal therapy with and without cetuximab, locally
advanced esophageal carcinoma.
Ph-lll: PFS 300 Accrual fulfilled,
results expected Q15
FFCD/FRENCH (ESOSTRATE trial) Operable oesophageal cancer with clinical complete
response after neoadjuvant chemoradiation randomised
between systematic surgery vs surveillance with selective
salvage surgery in case of operable recurrence
Ph-ll: Percentage of patients alive at 1 year >70 %
in the surveillance arm Ph-lll: DFS
Pts randomised
with cCR: Ph-ll:
114 Ph-lll: 260
1Q 2015
Open Versus Laparoscopically-assisted
Esophagectomy for Cancer (MIRO)
FREGAT NCT00937456
Hybrid MIO vs open oesophagectomy Ph. III: overall morbidity, DFS, OS, QoL, economical interest
of the surgical technique through a hospital point of view
200 Closed to
recruitement
MAGIC vs. CROSS Upper GI. ICORG
10–14, V3 (NEOAEGIS) NCT01726452
Phase III trial comparing neoadjuvant chemotherapy to
chemoradiation in junctional adenocarcinomas (NEOAEGIS)
Ph. III: OS, clinical and pathological response rate,
health-related QoL, tumour regression grade,
node-positivity, post-operative pathology, DFS, time to
treatment failure, toxicity, post-operative complications.
366 ongoing
PROTECT-01 trial FFCD-UNICANCER-FREGAT
(NCT02359968)
Phase II/III randomised comparison of preoperative
chemoradiation with paclitaxel-carboplatine or with
fluorouracil-oxaliplatine-folinic acid (FOLFOX) for
unresectable esophageal and junctional cancer
Ph II: complete surgical resection (R0) and severe
postoperative morbidity Ph III: overall survival
Ph II: 96 Ph III 400 Q1 2015
FREGAT database fregat-database.org French prospective national database collecting
epidemiological, clinical, pathological, biological, HRQOL
and social data on esophageal and gastric cancer
not applicable 15 000 On going
Art-Deco trial (NTR3532) Dose escalation in irresectable T4- tumours: 50.4 Gy versus
61. Gy plus carboplatin/paclitaxel
Ph. III: local tumour control in the esophagus 2x 130 patients Since 2012
Pre-SANO trial (NTR4834) Accuracy of assessment of tumour response after CROSS Prospective, non-randomised: correlation between
cCR and pCR 12 weeks after end of CROSS
140 Since 2013
Robot-assisted Thoraco-laparoscopic
Esophagectomy Versus Open
Transthoracic Esophagectomy
(ROBOT) NCT01544790
Evaluate the benefits, risks and costs of robot-assisted
thoraco-laparoscopic esophagectomy as an alternative to
open transthoracic esophagectomy as treatment for
esophageal cancer.
Ph-lll 112 Since 2012
Feasibility Study of Chemoradiation,
TRAstuzumab and Pertuzumab in
Resectable HER2+ Esophageal
Carcinoma (TRAP) NCT02120911
CROSS + Trastuzumab + Pertuzumab in HER positive
tumours
Ph I/II: Safety and efficacy; % of patients completing
trastuzumab and pertuzumab treatment
40 Since 2014
TOR trial NTR3060 RACE High dose CRT followed by exploratory thoracotomy
for cT4 tumours
The ability to achieve a radical (R0) resection. 30 2012
Prospective randomised comparison of neoadjuvant
radiochemotherapy versus chemotherapy in patients
with resectable adenocarcinomas of the
oesophago-gastric junction
Multicentre phase II/III trial with a 15 % improvement
of 3-year DFS by neoadjuvant radio-chemotherapy
compared to chemotherapy as primary endpoint
300 patients 2015
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European clinical research in gastrointestinal cancer.
The interdisciplinary and international nature of this col-
laboration has proven valuable. Interestingly, controversies
based on modality thinking did not appear (e.g. surgery vs.
radiotherapy) and generally a high acceptance of discrep-
ancy was present.
Based on the results of this analysis, the authors con-
clude that several areas of high controversy are amen-
able to future trials, some of which are either ongoing or
in advanced stages of planning (Table 5).
Although several controversial issues were identified,
not all could be “solved”. However, in some situations
certain ranges of what is considered “adequate” by the
selected experts could be established and may be helpful
in daily practice. Although these are not based on high
level evidence, we believe that the structured discussion
among experts can provide additional information for
clinical decision-making beyond available evidence in a
field where resources for studies are limited. A Summary
of key points is provided.
Conclusion - key points
 PET-CT for initial staging is considered to be a
valuable tool for the detection of additional
metastases and is also used for radiotherapy
planning.
 Despite limited published evidence, induction
chemotherapy is often being implemented.
Improvement of dysphagia, quick start of therapy
and control of systemic disease are the most
prominent reasons for this strategy.
 41.4–45 Gy are considered adequate in the
neoadjuvant setting. The dose for definitive CRT is
much more controversial, the opinions range from
50.4 Gy to over 60 Gy.
 After neoadjuvant CRT, restaging with CT scan is
sufficient, some countries repeat endoscopy. PET-CT
is not part of standard preoperative restaging so far.
 Most agreed on transhiatal resection for Siewert II
tumours and transthoracal approach for Siewert I
tumours (transthoracical en-bloc esophagectomy).
 Despite limited follow-up and high requirements
in expertise, in most centres, minimally invasive
surgery is considered an option, several studies
are ongoing.
 Squamous cell cancer
○ Most countries prefer definitive CRT for SCC
located in the upper thoracic oesophagus
○ Reasons preferring definitive CRT over surgery
independent of the location: patient preference,
co-morbidities, high biological age and high
perioperative risk.○ When cCR is achieved after neoadjuvant
therapy, omitting surgery could be an option when
supported by patient preference. However, this
option is not routinely recommended.
○ In the presence of a large tumour mass and
when the length of the tumour exceeds 10 cm a
surgical approach should be considered with
caution. T4b tumours should not be operated
when radiochemotherapy is feasible.
 Adenocarcinoma
○ In general neoadjuvant CRT is the treatment of
choice for adenocarcinoma of the junction
(Siewert I/II), the preference to include
radiotherapy increased with extension into the
oesophagus. Neoadjuvant chemotherapy alone is
the second best option, if trimodality therapy is
considered too risky (e.g. comorbidities, risk of
surgery). Then omitting radiotherapy instead of
surgery would be preferred.
○ Several practical reasons like co-morbidities,
poor performance status, etc. can lead to differ-
ent treatment recommendations.
Additional file
Additional file 1: Controversies: Treatment of oesophageal
carcinoma Survey 1.0.
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